IP Library › Patent Application 15818224
Patent Application
App. No. 15/818,224

Treatment for Athersclerosis

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/818,224
Abstract

A method is described to treat atherosclerosis by extracorporeally treating a patient's blood. A patient's blood is treated extracorporeally using a moiety that targets an antigen in the blood. The moiety facilitates removal of the blood antigen. The cleansed blood is then returned to the patient.

Claims (13)

1 . A method for treating atherosclerosis comprising:

a. removing blood from a patient in a first stage;

b. applying a treatment to the blood in a second stage; and

c. returning the blood to the patient in a third stage.

2 . The method of claim 1 , wherein the treatment includes

a. introducing an antibody that joins with an antigen in the blood to form an antibody-antigen complex; and

b. removing the complex form the blood.

3 . The method of claim 2 , wherein the targeted antigen is selected from a group consisting of Adipocyte fatty acid-binding protein (A-FABP, FABP4), NF-KB (Nuclear factor kappa-light-chain-enhancer of activated B cells), cyclooxygenase-2, Interleukin-6 (IL-6), Interleukin-1 (IL-1), Resistin (adipose tissue-specific secretory factor (ADSF), C/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein), Tumor necrosis factor-alpha (TNF-alpha), and IKB Kinase Beta (IKKB, IKK2), and combinations thereof.

4 . The method of claim 1 , wherein the treatment includes

a. introducing a targeted antibody that joins with an antigen in the blood to form an antibody-antigen complex;

b. conjugating the antibody-antigen complex with a second antibody comprising a moiety that increases efficacy of removal to form an antibody-moiety-antigen complex; and

c. removing the complex from the blood.

5 . The method of claim 4 , wherein the method includes testing the blood after the treatment and before returning the blood to the patient in order to determine efficacy of treatment.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2020
From: FELDER, MITCHELL S., DR.
To: MARV ENTERPRISES, LLC
Reel/Frame 052596/0052 →